Brain monoaminergic neurotransmission is involved in the pathophysiology of various psychiatric disorders including depression. Reliable indicators of central monoaminergic activity might be helpful to specifically identify and differentiate dysfunctions in individual patients in order to selectively adjust medication and predict clinical response.
In patients with depression, predictors of treatment response to serotonergic versus non-serotonergic (e.g., noradrenergic) antidepressants could be of considerable clinical relevance by avoiding unfavorable factors such as a prolonged duration of the disorder, risk of suicidality and therapy-resistance. Consequently, these tools might help to decrease direct and indirect costs of treatment.
The loudness dependence of the N1/P2 component of auditory evoked potentials (LD) has been proposed as a noninvasive neurophysiological indicator of central serotonergic function. This review focuses on recent studies providing evidence for the validity of LD as an indirect serotonergic marker and highlights data on the clinical application in terms of prediction of treatment response in patients with depression.
AdliMRushAJMollerHJBauerM. Algorithms for optimizing the treatment of depression: Making the right decision at the right time. Pharmacopsychiatry2003; 36 (suppl3): S222–229.
3.
ResslerKJNemeroffCB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety2000; 12 (suppl1): 2–19.
4.
JoycePRPaykelES. Predictors of drug response in depression. Arch Gen Psychiatry1989; 46(1): 89–99.
5.
YathamLNSteinerM. Neuroendocrine probes of serotonergic function: A critical review. Life Sci1993; 53(6): 447–463.
6.
MoorePLandoltHPSeifritzEClarkCBhattiTKelsoeJ. Clinical and physiological consequences of rapid tryptophan depletion. Neuropsychopharmacology2000; 23(6): 601–622.
7.
HegerlUJuckelG. Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: A new hypothesis. Biol Psychiatry1993; 33(3): 173–187.
8.
HegerlUJuckelG. Auditory evoked dipole source activity: Indicator of central serotonergic dysfunction in psychiatric patients?Pharmacopsychiatry1994; 27(2): 75–78.
9.
HegerlUJuckelGSchmidtLGRommelspacherH. Serotonergic ethanol effects and auditory evoked dipole activity in alcoholic and healthy subjects. Psychiatry Res1996; 63(1): 47–55.
10.
HegerlULipperheideKJuckelGSchmidtLGRommelspacherH. Antisocial tendencies and cortical sensory-evoked responses in alcoholism. Alcohol Clin Exp Res1995; 19(1): 31–36.
11.
AzmitiaECGannonPJ. The primate serotonergic system: A review of human and animal studies and a report on Macaca fascicularis. Adv Neurol1986; 43: 407–468.
12.
LewisDACampbellMJFooteSLMorrisonJH. The monoaminergic innervation of primate neocortex. Hum Neurobiol1986; 5(3): 181–188.
13.
JuckelGHegerlUMolnarMCsepeVKarmosG. Auditory evoked potentials reflect serotonergic neuronal activity: A study in behaving cats administered drugs acting on 5-HT1A autoreceptors in the dorsal raphe nucleus. Neuropsychopharmacology1999; 21(6): 710–716.
14.
SchergMPictonTW. Separation and identification of event-related potential components by brain electric source analysis. Electroencephalogr Clin Neurophysiol (suppl)1991; 42:24–37.
15.
HegerlUGallinatJMrowinskiD. Intensity dependence of auditory evoked dipole source activity. Int J Psychophysiol1994; 17(1): 1–13.
16.
TuchtenhagenFDaumannJNorraCGobbeleRBeckerSPelzS. High intensity dependence of auditory evoked dipole source activity indicates decreased serotonergic activity in abstinent ecstasy (MDMA) users. Neuropsychopharmacology2000; 22(6): 608–617.
17.
NorraCMrazekMTuchtenhagenFGobbeleRBuchnerHSassH. Enhanced intensity dependence as a marker of low serotonergic neurotransmission in borderline personality disorder. J Psychiatr Res2003; 37(1): 23–33.
18.
BruneauNBarthelemyCRouxSJouveJLelordG. Auditory evoked potential modifications according to clinical and biochemical responsiveness to fenfluramine treatment in children with autistic behavior. Neuropsychobiology1989; 21(1): 48–52.
19.
GallinatJBottlenderRJuckelGMunke-PuchnerAStotzGKussHJ. The loudness dependency of the auditory evoked N1/P2-component as a predictor of the acute SSRI response in depression. Psychopharmacology (Berl)2000; 148(4): 404–411.
20.
RoonKLSandorPSSchoonmanGGLamersFPSchoenenJFerrariMD. Auditory evoked potentials in the assessment of central nervous system effects of antimigraine drugs. Cephalalgia1999; 19(10): 880–885.
21.
HegerlUBottlenderRGallinatJKussHJAckenheilMMollerHJ. The serotonin syndrome scale: First results on validity. Eur Arch Psychiatry Clin Neurosci1998; 248(2): 96–103.
22.
PogarellOTatschKJuckelGHamannCMulertCPopperlG. Serotonin and dopamine transporter availabilities correlate with the loudness dependence of auditory evoked potentials in patients with obsessive-compulsive disorder. Neuropsychopharmacology2004; 29(10): 1910–1917.
23.
GallinatJSenkowskiDWernickeCJuckelGBeckerISanderT. Allelic variants of the functional promoter polymorphism of the human serotonin transporter gene is associated with auditory cortical stimulus processing. Neuropsychopharmacology2003; 28(3): 530–532.
24.
StrobelADebenerSSchmidtDHunnerkopfRLeschKPBrockeB. Allelic variation in serotonin transporter function associated with the intensity dependence of the auditory evoked potential. Am J Med Genet2003; 118B(1): 41–47.
25.
HegerlUGallinatJMrowinskiD. Sensory cortical processing and the biological basis of personality. Biol Psychiatry1995; 37(7): 467–472.
26.
MulertCJuckelGAugustinHHegerlU. Comparison between the analysis of the loudness dependency of the auditory N1/P2 component with LORETA and dipole source analysis in the prediction of treatment response to the selective serotonin reuptake inhibitor citalopram in major depression. Clin Neurophysiol2002; 113(10): 1566–1572.
27.
MulertCJagerLProppSKarchSStormannSPogarellO. Sound level dependence of the primary auditory cortex: Simultaneous measurement with 61-channel EEG and fMRI. Neuroimage2005; 28(1): 49–58.
28.
DierksTBartaSDemischLSchmeckKEnglertEKewitzA. Intensity dependence of auditory evoked potentials (AEPs) as biological marker for cerebral serotonin levels: Effects of tryptophan depletion in healthy subjects. Psychopharmacology (Berl)1999; 146(1): 101–107.
29.
DebenerSStrobelAKurschnerKKrancziochCHebenstreitJMaerckerA. Is auditory evoked potential augmenting/reducing affected by acute tryptophan depletion?Biol Psychol2002; 59(2): 121–133.
30.
MasseyAEMarshVRMcAllister-WilliamsRH. Lack of effect of tryptophan depletion on the loudness dependency of auditory event related potentials in healthy volunteers. Biol Psychol2004; 65(2): 137–145.
31.
UhlIGoryniaIGallinatJMulertCWutzlerAHeinzA. Is the loudness dependence of auditory evoked potentials modulated by the selective serotonin reuptake inhibitor citalopram in healthy subjects?Hum Psychopharmacol2006; 21(7): 463–471.
32.
KahkonenSJaaskelainenIPPennanenSLiesivuoriJAhveninenJ. Acute tryptophan depletion decreases intensity dependence of auditory evoked magnetic N1/P2 dipole source activity. Psychopharmacology (Berl)2002; 164(2): 221–227.
33.
NathanPJSegraveRPhanKLO'NeillBCroftRJ. Direct evidence that acutely enhancing serotonin with the selective serotonin reuptake inhibitor citalopram modulates the loudness dependence of the auditory evoked potential (LDAEP) marker of central serotonin function. Hum Psychopharmacol2006; 21(1): 47–52.
34.
von KnorringLPerrisC. Biochemistry of the augmenting-reducing response in visual evoked potentials. Neuropsychobiology1981; 7(1): 1–8.
LinkaTMullerBWBenderSSartoryG. The intensity dependence of the auditory evoked N1 component as a predictor of response to Citalopram treatment in patients with major depression. Neurosci Lett2004; 367(3): 375–378.
38.
HegerlUWulffHMuller-OerlinghausenB. Intensity dependence of auditory evoked potentials and clinical response to prophylactic lithium medication: A replication study. Psychiatry Res1992; 44(3): 181–190.
39.
HegerlUUlrichGMuller-OerlinghausenB. Auditory evoked potentials and response to lithium prophylaxis. Pharmacopsychiatry1987; 20(5): 213–216.
40.
HegerlUWulffHMuller-OerlinghausenB. Intensity dependence of auditory evoked potentials and clinical response to prophylactic lithium medication: A replication study. Psychiatry Res1992; 44(3): 181–190.
41.
LinkaTMullerBWBenderSSartoryGGastparM. The intensity dependence of auditory evoked ERP components predicts responsiveness to reboxetine treatment in major depression. Pharmacopsychiatry2005; 38(3): 139–143.
42.
JuckelGPogarellOAugustinHMulertCMüller-SiechenederFFrodlT. Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depression. J Clin Psychiatry2007, In press.
